BACKGROUND

• The 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM) assesses gene expression measurements from formalin-fixed paraffin-embedded primary tumor tissue to predict tumor recurrence or metastasis risk.

• The 31-GEP returns a continuous probability score between zero and one to stratify risk into one of three risk categories: lowest (Class 1A; 0-0.41), intermediate (Class 1B/2A; 0.42-0.58), and highest (Class 2B; 0.59-1) and has been validated in multiple prospective and retrospective studies.1-14

OBJECTIVE

Understand the clinical use of the 31-GEP test specifically by nurse practitioners and physician assistants (NP/PAs).

METHODS

During 2020, an IRB approved 20-question survey study was conducted during two national dermatology conferences, one included physicians and NP/PAs and one was limited to NP/PAs. The survey was designed to assess the attitudes of NP/PAs towards prognostic testing of CM, and specifically, NP/PA’s and one was limited to NP/PA’s. The survey was designed to assess additional data presentation, and respondents received modest remuneration. About the 31-GEP test. Participation was voluntary, not associated with a clinical context, and respondents were asked to report their usual practice for these questions.

RESULTS

• The 31-gene expression profile (31-GEP) test for cutaneous melanoma (CM) assesses gene expression measurements from formalin-fixed paraffin-embedded primary tumor tissue to predict tumor recurrence or metastasis risk.

• The 31-GEP returns a continuous probability score between zero and one to stratify risk into one of three risk categories: lowest (Class 1A; 0-0.41), intermediate (Class 1B/2A; 0.42-0.58), and highest (Class 2B; 0.59-1) and has been validated in multiple prospective and retrospective studies.1-14

What are the benefits of prognostic testing?

Knowledge/Understanding

Personalized Treatment

Reduced Uncertainty

Life Planning

None

Figure 2. Most NP/PAs responded that prognostic testing was beneficial for patient care. Of NP/PAs that answered, ‘did not know’, most were not users of the 31-GEP test (box inset).

Figure 3. Top. Increased knowledge and personalized treatment were the top benefits reported by respondents. Bottom. Of 31-GEP users, most said that the test was valuable for follow-up, imaging and treatment guidance, and to inform referral decisions.

Figure 4. Number of respondents who would alter patient management for a T1 tumor (left) or stage I melanoma (right) that received a high risk 31-GEP Class 2B result. Insets reflect the number of respondents who would change management based on whether they use the 31-GEP test.

Figure 5. Most NP/PAs were very or somewhat likely to recommend the 31-GEP test to a colleague. Specifically, among users of the 31-GEP test, 99% responded that they would recommend the test to a colleague.

CONCLUSIONS

• 99% of 31-GEP users would recommend the test to a colleague.

• 89% of NP/PAs responded that prognostic testing, particularly the 31-GEP, could improve patient care.

• Most 31-GEP test users would consider patient management changes for patients with a T1 tumor (82%) or stage I melanoma (81%) that received a Class 2B result.

REFERENCES, FUNDING & DISCLOSURES


Funding: This study was sponsored by Castle Biosciences, Inc.. The authors are employees and options holders of Castle Biosciences, Inc.